Long Washout Periods Between Biologics for Inflammatory Bowel Disease Clinical Trials Are Unnecessary: A Canadian Retrospective Cohort Study

Sudheer K Vuyyuru; Meagan Archer; Tran M Nguyen; Melanie Beaton; Vipul Jairath

doi:10.14309/ajg.0000000000002398

Long Washout Periods Between Biologics for Inflammatory Bowel Disease Clinical Trials Are Unnecessary: A Canadian Retrospective Cohort Study

Am J Gastroenterol. 2023 Dec 1;118(12):2290-2293. doi: 10.14309/ajg.0000000000002398. Epub 2023 Jul 6.

Authors

Sudheer K Vuyyuru¹, Meagan Archer², Tran M Nguyen², Melanie Beaton¹, Vipul Jairath^{1

2

3}

Affiliations

¹ Division of Gastroenterology, Department of Medicine, Schulich school of Medicine, Western University, London, Ontario, Canada.
² Lawson Health Research Institute, Western University, London, Ontario, Canada.
³ Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.

PMID: 37410920
DOI: 10.14309/ajg.0000000000002398

Abstract

Introduction: To assess the safety of early vs late biologic switch in patients with inflammatory bowel disease.

Methods: In this retrospective study, we included patients with inflammatory bowel disease who underwent biologic switch between January 2014 and July 2022 at a tertiary center. The primary outcome was any infection by 6 months.

Results: There was no statistically significant difference between patients who had early biologic switch (≤30 days, n = 51) and late switch (>30 days, n = 77) in either infectious or noninfectious adverse events by 6 and 12 months.

Discussion: Early biologic switch is safe. A prolonged washout period between 2 biologics is unnecessary.

MeSH terms

Biological Products* / adverse effects
Canada
Humans
Inflammatory Bowel Diseases* / chemically induced
Inflammatory Bowel Diseases* / drug therapy
Retrospective Studies

Substances

Biological Products